Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Connect Biopharma Holdings (CNTB) EBITDA Margin (2024 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed EBITDA Margin for 2 consecutive years, with 106887.5% as the latest value for Q3 2025.

  • Quarterly EBITDA Margin fell 10587798.0% to 106887.5% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 85945.31% through Dec 2025, down 8588275.0% year-over-year, with the annual reading at 85945.31% for FY2025, 8588275.0% down from the prior year.
  • EBITDA Margin hit 106887.5% in Q3 2025 for Connect Biopharma Holdings, down from 26393.75% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 61.9% in Q2 2024 to a low of 106887.5% in Q3 2025.